Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amarin (AMRN) Still Risky into NCE Amid Vascepa Sales Staff Additions, Financing - Analyst
December 7, 2012 7:20 AM ESTAmarin (Nasdaq: AMRN) is in the dumps Friday morning following a news release Thursday night that it was entering a non-equity financing agreement for $100 million and hiring about 250 to 300 reps for its Vascepa launch.
Today, Wedbush is out with some comments on the news today.
Wedbush said the timing of the release was a surprise following... More
Amarin (AMRN) Vascepa Pricing Leak?
December 3, 2012 3:21 PM ESTAmarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although... More
Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed
November 29, 2012 8:54 AM ESTAmarin Corp Plc (NASDAQ: AMRN) is higher early Thursday amid news the company is delaying the hiring of a sales force until December versus November.
While on the surface this news would seem neutral-to-negative, speculators view this as an indications that... More
